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Article
The development of multimorbidity during
16 years after diagnosis of type 2 diabetes
Sandra Pouplier1 , Maria A˚hlander Olsen1,
Tora Grauers Willadsen1 , Ha˚kon Sandholdt1, Volkert Siersma1,
Christen Lykkegaard Andersen1 and Niels de Fine Olivarius1
Abstract
Objective: The aims of this study were to (1) quantify the development and composition of multimorbidity (MM) during
16 years following the diagnosis of type 2 diabetes and (2) evaluate whether the effectiveness of structured personal
diabetes care differed between patients with and without MM. Research design and methods: One thousand three
hundred eighty-one patients with newly diagnosed type 2 diabetes were randomized to receive either structured personal
diabetes care or routine diabetes care. Patients were followed up for 19 years in Danish nationwide registries for the
occurrence of outcomes. We analyzed the prevalence and degree of MM based on 10 well-defined disease groups. The
effect of structured personal care in diabetes patients with and without MM was analyzed with Cox regression models.
Results: The proportion of patients with MM increased from 31.6% at diabetes diagnosis to 80.4% after 16 years. The
proportion of cardiovascular and gastrointestinal diseases in surviving patients decreased, while, for example, muscu-
loskeletal, eye, and neurological diseases increased. The effect of the intervention was not different between type 2
diabetes patients with or without coexisting chronic disease. Conclusions: In general, the proportion of patients with
MM increased after diabetes diagnosis, but the composition of chronic disease changed during the 16 years. We found
cardiovascular and musculoskeletal disease to be the most prevalent disease groups during all 16 years of follow-up. The
post hoc analysis of the intervention showed that its effectiveness was not different among patients who developed MM
compared to those who continued to have diabetes alone.
Keywords
Multimorbidity, comorbidity, type 2 diabetes, chronic diseases, patient-centered care, intervention, primary care, general
practice, post hoc analysis.
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Introduction
In recent decades, more effective treatments and longer
survival have led to a higher proportion of patients living
with two or more coexisting chronic diseases, also known
as multimorbidity (MM).1–3 In primary care, more than
two-thirds of patients aged 50 years or over have MM,2
and MM increases with age and relatively low socioeco-
nomic status.2,4,5 MM is a challenge to the health care
system as it is associated with reduced physical function,6
an experience of fragmented care,7 increased mortality,8,9
and increased health-care costs.3 The most common
chronic disease in MM patients is diabetes,10–12 followed
by stroke, cancer, ischemic heart disease, and chronic
obstructive pulmonary disease (COPD).12 For MM patients
with diabetes, morbidity and mortality increase with the
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number of additional chronic conditions.8,13 The treatment
of patients with MM is also complicated by conflicting
treatment guidelines,14 and because of changing health
needs, it has been proposed to replace disease-oriented care
with patient-centered care in MM patients.15 Since diabetes
patients constitute a patient group with high risk of devel-
oping MM, it is important to identify the composition of
diseases developed after diabetes diagnosis. Furthermore,
few studies have focused on the development of MM in a
longitudinal setting.16,17
Objectives
The Diabetes Care in General Practice (DCGP) study
included a large population-based sample of patients newly
diagnosed with type 2 diabetes, and the study tested the
effectiveness of structured personal diabetes care in a ran-
domized design.18 The aim of the present study was to
answer three research questions:
1. How many of the newly diagnosed type 2 diabetes
patients developed MM during 16 years after dia-
betes diagnosis, according to a clinically relevant
definition?
2. How was the composition of MM over time among
type 2 diabetes patients?
3. Did the intervention of structured personal care
have a statistically significant different effect on the
seven predefined outcomes in patients with and
without MM?
Research design and methods
The DCGP study was an open, cluster-randomized, con-
trolled trial of the effect of structured personal diabetes care
versus routine care with 474 general practitioners (GPs),
who volunteered to participate (ClinicalTrials.gov
NCT01074762). A detailed description of the DCGP study
design has previously been reported by Hansen et al.18 The
Copenhagen and Frederiksberg Research Ethics Commit-
tee approved the DCGP study.
Patients
The participating GPs were asked to include all patients on
their practice lists who were aged 40 years or over and
newly diagnosed with type 2 diabetes during 2 years in
1989–1991, but 71 intervention doctors volunteered to
recruit patients for a further year (Figure 1). Following
recruitment, diabetes diagnosis was confirmed by a single
fasting whole-blood/plasma glucose concentration (7.0/
8.0 mmol/l) measured at a major laboratory. The protocol-
based exclusion criteria were life-threatening somatic
disease, severe psychiatric disease, or unwillingness to par-
ticipate (Figure 1). As previously reported, the randomiza-
tion was balanced.18 Of the 1381 patients in the final study
population, 1369 (99.1%) patients were of Western Eur-
opean descent. Based on whether insulin treatment was
started and continued within 180 days after diabetes diag-
nosis, approximately 97.5% of the patients were considered
to have type 2 diabetes.19
Intervention
The intervention began when a patient was included in the
study from March 1, 1989 to February 28, 1992, and it was
terminated for all patients on September 26, 1995. The
intervention patients were offered follow-up every 3
months and annual screening for diabetes complications.
The consultations focused on risk factor control (glycemia,
blood pressure, and lipid profile) and lifestyle changes
(diet, weight reduction, smoking cessation, and increased
physical activity).19 Together the patient and the doctor
defined attainable goals for control of important risk fac-
tors, and at each quarterly follow-up consultation, they
were asked to compare achievements with goals and to
consider adjusting goal or treatment accordingly. Further
details about the intervention have previously been
described.18
Clinical and registry-based follow-up
To examine objectives 1 and 2, we used registry-based
follow-up on all newly diagnosed type 2 diabetes patients.
Both intervention and control group were included in these
analyses.
A clinical follow-up examination was completed for 970
(93.4%) of 1039 surviving patients (Figure 1) after a med-
ian (interquartile range) of 5.57 (4.96–6.16) years in the
structured personal care group and 5.85 (5.30–6.45) years
in the routine care group.
A description of all variables and definitions has previ-
ously been published.18
The following Danish registries provided information
about MM and the predefined outcomes of the trial: (1)
Information on vital and emigration status of all patients
were ascertained through the Danish Civil Registration
System (CRS) using the unique personal identification
number assigned to all residents living in Denmark, which
enables unambiguous linkage between study populations
and all Danish national registries.20 All surviving patients
were censored on December 31, 2008, using CRS. (2) The
Danish Register of Causes of Death supplied information
about underlying and possible contributory causes of
death.21 In four patients, the cause of death was not
recorded. (3) Information on cancer diagnoses was from
The Danish Cancer Registry.22 (4) The Danish National
Patient Register gave information on hospital contacts in
Denmark, for example, discharge diagnoses and surgical
procedures performed.23 (5) Psychiatric diagnoses, how-
ever, were from the Danish Psychiatric Central Research
Register of patients treated at psychiatric departments.24
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MM was defined as having diabetes and at least one
other chronic condition from 1 of 10 different diagnosis
groups: lung, musculoskeletal, thyroid, mental illness, can-
cer, neurological, gastrointestinal, cardiovascular, chronic
kidney, and eye disease. Each group contained preselected
diagnosis and procedure codes, coded as International Clas-
sification of Diseases, 10th edition (ICD-10) and the earlier
version 8th edition (ICD-8)25 and Nordic Classification of
Surgical Procedures.26 If patients had more than one diag-
nosis within a diagnosis group, we counted this as only one
comorbidity when estimating the degree of MM. Some of
the outcomes contained diagnoses that were also included
in the definition of MM. If the patient shifted status from
diabetes alone to MM due to the occurrence of an outcome,
the change in status was registered after the occurrence of
the outcome. We only included the first occurrence of an
outcome in the analyses. All later incident cases of the
same outcome were not included. At diabetes diagnosis,
MM was estimated by looking 10 years back in time,
except for psychiatric diagnoses that were used without any
time limit. The diagnoses were selected based on the fol-
lowing criteria: chronic condition, high prevalence in the
general population, relevance for primary care, condition
associated with reduced life expectancy, condition of a
certain severity, and/or associated with a considerable dis-
ease burden for patients (Online Supplemental Material,
Table S1). The predefined outcomes of the randomized trial
were all-cause mortality, diabetes-related death, “any
Figure 1. Patient flow.
Pouplier et al. 3
diabetes-related endpoint”, myocardial infarction, stroke,
peripheral vascular disease, and microvascular disease18
(Online Supplemental Material, Table S2).
Statistical analysis
For objectives 1 and 2, only data from up to 16 years after
diabetes diagnosis were used in the analyses as the inclu-
sion phase lasted for 3 years. For objective 3, the full data
set with up to 19 years of follow-up was used, and we
investigated the incidence of the predefined outcomes in
Cox regression models where the diagnosis of MM was a
time-varying covariate. This means that the same patient
could have contributed to both the diabetes mellitus and the
MM group when analyzing outcomes. The Cox model was
fit by maximizing the partial likelihood and the baseline
survivor function computed using the Breslow estimate.
Hazard ratios (HRs) for the intervention effect were calcu-
lated for patients with and without MM, respectively, and
95% confidence intervals (CIs) and p values were deter-
mined using a sandwich estimator for the variance to
account for clustering of patients within practices.27 The
assessments of the intervention effects were adjusted for
the following variables at diagnosis: age, sex, cohabitation
status, education, body mass index, hypertension, diagnos-
tic fasting plasma glucose, total cholesterols, physical
activity, and smoking. Patients with missing values in one
or more variables were omitted from the analyses where
these variables were included. Incidence rates for each out-
come were calculated as the number of patients experien-
cing the corresponding outcome divided by the person time
at risk, that is, from diagnosis to the first occurrence of the
outcome, death, or end of follow-up. Patients with any
occurrence of an outcome before diabetes diagnosis were
excluded from the analyses pertaining to that outcome.
Analyses were done in SAS (version 9.4). The level of
statistical significance was p < 5%.
Results
At diabetes diagnosis, 31.6% of the patients had MM. The
proportion of MM patients increased after diagnosis to
80.4% after 16 years. During the same period, the propor-
tion of patients with diagnoses from two or more disease
groups besides diabetes increased from 8.1% to 47.6%. The
emergence of still higher degrees of MM in surviving
patients during the 16 years after diabetes diagnosis is illu-
strated in Figure 2.
Compared to patients with diabetes alone, patients with
MM were older and more often lived alone (Table 1).
Furthermore, they were less physically active and more
likely to suffer from hypertension and to report relatively
low self-rated health.
During the first 16 years after the diagnosis of type 2
diabetes, the most prevalent chronic conditions in surviving
patients were cardiovascular and musculoskeletal diseases
(Figure 3). While the prevalence of cardiovascular diseases
declined, it increased for musculoskeletal diseases. Preva-
lence of both neurological diseases and eye diseases
increased during follow-up and were eventually the third
and fourth most common disease group among the MM
diabetes patients.
For each of the seven predefined outcomes, the inci-
dence rate was greater among patients with MM than
among patients with diabetes alone during the 19 years of
follow-up (Table 2). In the main trial, the intervention
reduced the risk of myocardial infarction and “any
diabetes-related endpoint”,18 while in the present post hoc
analysis, the intervention only reduced the incidence of
“any diabetes-related endpoint”—and only in patients with
MM (Table 2). The effectiveness of the intervention, how-
ever, did not show a statistically significant difference
between patients with and without MM for any outcome,
and there was no clear trend as to whether the intervention
effect was relatively larger or smaller among MM patients
compared to patients with diabetes only.
The intervention did not influence the emergence of
MM in a multivariable adjusted Cox model (structured care
vs. routine care: adjusted HR, 0.87; 95% CI, 0.75–1.01; p¼
0.059).
Conclusions
This study found increasing prevalence and changing com-
position of MM during the first 16 years after the diagnosis
of type 2 diabetes. Furthermore, structured personal dia-
betes care reduced the incidence of the aggregate outcome,
“any diabetes-related endpoint,” by 28% among patients
with MM. There were no statistically significant differ-
ences in the intervention effect between patients with and
Figure 2. The development of MM during 16 years after diabetes
diagnosis. Orange: diabetes only; light blue: diabetes þ one
chronic disease; green: diabetes þ two chronic diseases; yellow:
diabetes þ three chronic diseases; blue: diabetes þ four chronic
diseases; red: diabetes þ five chronic diseases. MM:
multimorbidity.
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without MM for this or any of the other six predefined
outcomes.
Research in MM is in its infancy, and there is no agree-
ment on how it is defined. It is acknowledged, however,
that the diseases included in the definition of MM should be
the most prevalent and those with a high burden of dis-
ease.28,29 In line with this view, we chose a relatively sim-
ple definition of MM that would be easy to implement in
clinical practice using 10 diagnoses groups of chronic
diseases. Each group contained preselected clinically
linked diagnoses with similarities in pathophysiological
risk profile and treatment.30 Our definition was partly
based on previous recommendations on defining MM.28,31
In the definitions of MM, the most common disease
constituting MM was found to be diabetes, followed by
stroke, cancer, ischemic heart disease, and COPD.12 In a
study examining chronic comorbidity clusters in patients
with type 2 diabetes, the most common diseases were
Table 1. Characteristics of patients with and without MM at diabetes diagnosis and 6 years later.a
At diabetes diagnosis Six years after diabetes diagnosis
N (DM
alone/MM) DM alone MM
N (DM alone/
MM) DM alone MM
Sociodemographic
Age (years) 964/417 64.1 (54.0–72.7) 67.3 (59.4–75.2) 490/480 66.4 (57.3–74.9) 71.4 (62.8–79.0)
Male gender 964/417 509 (52.8) 224 (53.7) 541/528d 279 (51.6) 271 (51.33)
Live aloneb 942/407 283 (30.0) 151 (37.1) 467/443 145 (31.1) 178 (40.2)
Basic school education 916/395 708 (77.3) 325 (82.3) 523/499d 388 (74.2) 404 (81.0)
Clinical
Body mass index (kg/m2) 958/414 29.0 (26.0–32.7) 29.3 (26.3–32.6) 483/464 28.4 (25.7–31.8) 28.3 (25.1–32.1)
Hypertension (yes) 964/417 683 (70.9) 343 (82.3) 490/480 330 (67.4) 379 (79.0)
Systolic blood pressure
(mmHg)
959/415 150 (130–160) 150 (130–160) 487/474 150 (135–160) 148.5 (130–160)
Diastolic blood pressure
(mmHg)
959/415 85 (80–90) 80 (80–90) 487/474 85 (80–90) 80 (76–90)
Biochemical
Hemoglobin A1c (%)c 827/309 10.2 (8.8–11.8) 9.9 (8.4–11.6) 483/470 8.7 (7.9–9.9) 8.5 (7.6–9.7)
Hemoglobin A1c (mmol/mol) 827/309 88 (73–105) 85 (68–103) 483/470 72 (63–85) 69 (60–83)
Fasting plasma glucose 964/417 13.9 (10.8–17.2) 13.2 (10.3–16.6) 378/348 8.5 (6.9–10.9) 8.3 (6.5–13.9)
Total cholesterol (mmol/l) 945/405 6.2 (5.4–7.1) 6.2 (5.4–7.2) 483/469 6.0 (5.3–6.8) 6.0 (5.2–6.9)
Fasting triglycerides (mmol/l) 943/403 1.9 (1.4–2.9) 2.1 (1.5–3.0) 442/417 1.7 (1.2–2.5) 1.9 (1.4–2.8)
Serum creatinine (mol/l) 946/405 88 (79–98) 93 (82–107) 483/469 87 (79–99) 94 (81–109)
Urinary albumin 928/390 468/439
Normal 539 (58.1) 221 (56.7) 300 (64.1) 247 (56.3)
Microalbuminuria 345 (37.2) 148 (38.0) 158 (33.8) 158 (36.0)
Proteinuria 44 (4.7) 21 (5.3) 10 (2.1) 34 (7.7)
Behavioralb
Sedentary physical activity
(yes)
939/406 225 (24.0) 147 (36.2) 465/436 99 (21.3) 172 (39.5)
Current smoking (yes) 940/406 348 (37.0) 124 (30.5) 461/442 145 (31.5) 133 (30.1)
Patient attitudesb
Self-rated health 943/407 943 (100) 407 (100) 468/441 468 (100) 441 (100)
Excellent 133 (14.1) 26 (6.4) 113 (24.2) 58 (13.2)
Good 360 (38.2) 88 (21.6) 218 (46.6) 148 (33.6)
Fair 375 (39.8) 230 (56.5) 127 (27.1) 200 (45.4)
Poor/very poor 75 (8.0) 63 (15.5) 10 (2.1) 35 (7.9)
Process of careb
Number of consultations last
year
489/480 6 (4–9) 7 (5–11.5)
Number of diabetes-related
consultations
489/480 4 (3–6) 4 (3–6)
DM: diabetes mellitus; MM: multimorbidity; IQR: interquartile range.
aValues are medians (IQR) or numbers (percentages of group).
bData from questionnaires to patients (behavioral) or their general practitioners (process of care).
cThe diagnostic value is limited to measurements from within 45 days of diabetes diagnosis. Reference range: 5.4–7.4%.
dFor these variables, the totals refer to the number of patients alive when the 6-year examination was initiated.
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cardiovascular and musculoskeletal diseases, just as we
found in the present study.32
In accordance with clinical experience, we found that the
degree ofMM increased markedly after the diagnosis of type
2 diabetes; the prevalence of MM, defined as having at least
one chronic disease besides diabetes, increased from 31.6%
at diagnosis to 80.4% during the first 16 years after diabetes
diagnosis. Because of the large variation in definitions of
MM in the existing literature, these results could not be
compared with the results from other studies.8,10–12,28
While the observed increase in the prevalence of eye
diseases after diabetes diagnosis was expected,33 the
decrease in cardiovascular disease was probably a result of
selective survival. One of our interesting findings was the
relatively high proportion of multimorbid diabetes patients
having musculoskeletal disease. In the present study, kidney
disease was rare, but in our definition of MM, with prese-
lected chronic diagnoses, we only included severe chronic
kidney diseases, which generated hospital contacts.
We found that MM was associated with relatively high
age, living alone, sedentary lifestyle, and relatively low
self-rated health. These observations were in accordance
with previous MM research.1–5,34–37
This study meets a previously expressed need for exam-
ining the effectiveness of a patient-centered approach in the
management of patients with diabetes and coexisting
chronic morbidities.32 In a recent post hoc analysis of the
DCGP study, we found an especially pronounced effect of
structured personal care among patients with a severe psy-
chiatric disease.38 Although the diabetes patients with MM
in the DCGP study were also at high risk of developing
serious outcomes (Table 2), the effect of the same interven-
tion did not differ between patients with or without coex-
isting chronic disease. The DCGP study implemented
self-management in the shape of collaborative goal setting,
self-efficacy strategies, and a close doctor–patient relation-
ship—a strategy that is being increasingly recognized as a
key component for improving the health status of people
with multiple chronic conditions.39 A recently updated
Cochrane review40 on interventions for patients with MM
also concluded that interventions targeting the management
of specific risk factors or focused areas of increased diffi-
culty were more likely to be effective. Lately, methods
have been developed for managing patients with MM in
primary care: like the DCGP study, these methods involve
realistic goal setting based on the prioritization of health
problems, taking the patient’s preferences into account,41,42
and there is a great need for further intervention research
within this area.
Strengths and limitations
The results from this post hoc analysis of the DCGP trial
should be interpreted as observational since these analyses
were not mentioned in the original study protocol. Even
though the GPs volunteered to participate in the study,
we believe that the patients included in the DCGP study
were not different from patients having doctors not willing
to participate, because the GPs were recruited from all over
Denmark, making the study sample representative for the
patients with newly diagnosed type 2 diabetes in Denmark
at the time the study was conducted.19 Further strengths
were the relatively large sample of newly diagnosed
patients, the long follow-up, and the availability of many
confounders for the multivariate adjustments.
The five major Danish national registries used to ascer-
tain both outcomes and the development of MM in the
present analyses are believed to have high completeness
and accuracy (Online Supplemental Material, Tables S1
and S2).20–24 Previous studies on Australian hospital
administrative data on discharge diagnoses showed a sig-
nificant underreporting of comorbidities.43 The Danish
National Patient Register contains diagnoses and procedure
codes from both inpatient and outpatient wards and is not
limited to discharge diagnoses; however, it has served as a
basis for payment to the public hospitals since 2000, and
since this study also extracted data before this period, it is a
possible limitation that the completeness has not been as
accurate before the year of 2000.
This way of defining MM disregarded diagnoses made
in general practice alone, such as minor psychiatric disor-
ders, moderate asthma, and all levels of kidney disease,
which would not get treated or registered in accordance
with contacts in the secondary sector. On the other hand,
it could be regarded as a strength that our definition of MM
rested on diagnoses from secondary care, as this implied
relatively high severity of the diseases that we included in
our analyses. Since we included both inpatient and outpa-
tient hospital wards, an actual hospitalization was not
required. Even though we made a thorough preselection
and included a high number of prevalent and serious diag-
noses, it is a limitation that some rare but important diag-
noses could have been overlooked resulting in some
severely ill persons not being considered as such. However,
Figure 3. The prevalence of 10 disease groups during 16 years
after diabetes diagnosis.
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7
when defining MM, a limited number of preselected diag-
noses are widely used.4,10,12,44
In conclusion, 80% of patients with type 2 diabetes had
MM 16 years after diabetes diagnosis. Cardiovascular and
musculoskeletal diseases were the most prevalent morbid-
ities. While musculoskeletal, neurological, eye, and
chronic kidney diseases increased after diabetes diagnosis,
the prevalence of cardiovascular, gastrointestinal, mental
illness, cancer, and lung diseases decreased. The risk of all
outcomes was significantly greater for patients with MM
compared to patients having diabetes only. The interven-
tion of structured personal diabetes care, however, lowered
the risk of the aggregate outcome, “any diabetes-related
endpoint”, but this result was not obtained for the remain-
ing outcomes and the intervention effect was not different
between patients with and without MM. High-risk patients
with MM, however, did seem at least as susceptible to
interventions as type 2 diabetes patients without
comorbidities.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The authors received no financial support for the research, author-
ship, and/or publication of this article.
ORCID iD
Sandra Pouplier http://orcid.org/0000-0002-2625-7440
Tora Grauers Willadsen http://orcid.org/0000-0001-7240-1944
Supplemental material
Supplemental material for this article is available online.
References
1. Britt HC, Harrison CM, Miller GC, et al. Prevalence and
patterns of multimorbidity in Australia. Med J Australia
2008; 189(2): 72–77. http://www.ncbi.nlm.nih.gov/pubmed/
18637770 (accessed 8 January 2018).
2. Glynn LG, Valderas JM, Healy P, et al. The prevalence of
multimorbidity in primary care and its effect on health care
utilization and cost. Fam pract 2011; 28(5): 516–523. DOI:
10.1093/fampra/cmr013.
3. Uijen AA and van de Lisdonk EH. Multimorbidity in primary
care: prevalence and trend over the last 20 years. Eur J Gen
Pract 2008; 14(suppl 1): 28–32. DOI: 10.1080/
13814780802436093.
4. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of
multimorbidity and implications for health care, research, and
medical education: a cross-sectional study. Lancet 2012;
380(9836): 37–43. DOI: 10.1016/S0140-6736(12)60240-2.
5. van den Akker M, Buntinx F, Metsemakers JF, et al. Multi-
morbidity in general practice: prevalence, incidence, and
determinants of co-occurring chronic and recurrent diseases.
J Clin Epidemiol 1998; 51(5): 367–375. http://www.ncbi.
nlm.nih.gov/pubmed/9619963 (accessed 8 January 2018).
6. Bayliss EA, Bayliss MS,Ware JE, et al. Predicting declines in
physical function in persons with multiple chronic medical
conditions: what we can learn from the medical problem list.
Health Qual Life Out 2004; 2: 47. DOI: 10.1186/1477-7525-
2-47.
7. Burgers JS, Voerman GE, Grol R, et al. Quality and coordi-
nation of care for patients with multiple conditions: results
from an international survey of patient experience. Eval
Health Prof 2010; 33(3): 343–364. DOI: 10.1186/1477-
7525-2-47.
8. France EF, Wyke S, Gunn JM, et al. Multimorbidity in pri-
mary care: a systematic review of prospective cohort studies.
Brit J Gen Pract 2012; 62(597): e297–e307. DOI: 10.3399/
bjgp12X636146.
9. Librero J, Peiro S and Ordinana R. Chronic comorbidity and
outcomes of hospital care: length of stay, mortality, and read-
mission at 30 and 365 days. J Clin Epidemiol 1999; 52(3):
171–179. http://www.ncbi.nlm.nih.gov/pubmed/10210233
(accessed 8 January 2018).
10. Diederichs C, Berger K and Bartels DB. The measurement of
multiple chronic diseases—a systematic review on existing
multimorbidity indices. J Gerontol A-Biol 2011; 66(3):
301–311. DOI: 10.1093/gerona/glq208.
11. Sinnige J, Braspenning J, Schellevis F, et al. The prevalence
of disease clusters in older adults with multiple chronic dis-
eases—a systematic literature review. PloS one 2013; 8(11):
e79641. DOI: 10.1371/journal.pone.0079641.
12. Willadsen TG, Bebe A, Koster-Rasmussen R, et al. The role
of diseases, risk factors and symptoms in the definition of
multimorbidity—a systematic review. Scand J Prim Health
2016; 34(2): 1–10. DOI: 10.3109/02813432.2016.1153242.
13. Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and
mortality in older adults: a systematic review and meta-anal-
ysis. Arch Gerontol Geriat 2016; 67: 130–138. DOI: 10.1016/
j.archger.2016.07.008.
14. Fortin M, Contant E, Savard C, et al. Canadian guidelines for
clinical practice: an analysis of their quality and relevance to
the care of adults with comorbidity. BMC fam pract 2011; 12:
74. DOI: 10.1186/1471-2296-12-74.
15. Starfield B. Challenges to primary care from co- and multi-
morbidity. Prim Health Care Res 2011; 12(1): 1–2. DOI: 10.
1017/S1463423610000484.
16. Caughey GE, Ramsay EN, Vitry AI, et al. Comorbid chronic
diseases, discordant impact on mortality in older people: a 14-
year longitudinal population study. J Epidemiol Commun H
2010; 64(12): 1036–1042. DOI: 10.1136/jech.2009.088260.
17. Menotti A, Mulder I, Nissinen A, et al. Prevalence of mor-
bidity and multimorbidity in elderly male populations and
their impact on 10-year all-cause mortality: The FINE study
(Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001;
54(7): 680–686. http://www.ncbi.nlm.nih.gov/pubmed/1143
8408 (accessed 8 January 2018).
18. Hansen LJ, Siersma V, Beck-Nielsen H, et al. Structured
personal care of type 2 diabetes: a 19 year follow-up of the
8 Journal of Comorbidity
study Diabetes Care in General Practice (DCGP). Diabetolo-
gia 2013; 56(6): 1243–1253. DOI: 10.1007/s00125-013-
2893-1.
19. Olivarius NF, Beck-Nielsen H, Andreasen AH, et al. Rando-
mised controlled trial of structured personal care of type 2
diabetes mellitus. BMJ (Clinical research ed) 2001;
323(7319): 970–975. http://www.ncbi.nlm.nih.gov/pubmed/
11679387 (accessed 8 January 2018).
20. Pedersen CB, Gotzsche H, Moller JO, et al. The Danish Civil
Registration System. A cohort of eight million persons. Dan
Med Bull 2006; 53(4): 441–449. http://www.ncbi.nlm.nih.
gov/pubmed/17150149 (accessed 8 January 2018).
21. Helweg-Larsen K. The Danish Register of Causes of Death.
Scand J Public Healt 2011; 39(7 Suppl): 26–29. DOI: 10.
1177/1403494811399958.
22. GjerstorffML. TheDanishCancer Registry. Scand J PublicHealt
2011; 39(7 Suppl): 42–45. DOI: 10.1177/1403494810393562.
23. Lynge E, Sandegaard JL and Rebolj M. The Danish National
Patient Register. Scand J Public Healt 2011; 39(suppl 7):
30–33. DOI: 10.1177/1403494811401482.
24. Mors O, Perto GP and Mortensen PB. The Danish Psychiatric
Central Research Register. Scand J Public Healt 2011;
39(suppl 7): 54–57. DOI: 10.1177/1403494810395825.
25. ICD-10, International Statistical Classification of Diseases
and Related Health Problems 10th Revision, Instruction Man-
ual. World Health Organization, 2010. http://www.who.int/
classifications/icd/ICD10Volume2_en_2010.pdf (accessed 8
January 2018).
26. NOMESCO Classification of Surgical Procedures (NCSP).
http://www.nordclass.se/ncsp_e.htm. (accessed 8 January
2018).
27. Kalbfleisch JDPR. The statistical analysis of failure time
data. 2nd ed. New York: Wiley, 2002.
28. Fortin M, Stewart M, Poitras ME, et al. A systematic review
of prevalence studies on multimorbidity: toward a more uni-
form methodology. Ann Fam Med 2012; 10(2): 142–151.
DOI: 10.1370/afm.1337.
29. Le Reste JY, Nabbe P, Manceau B, et al. The European
General Practice Research Network presents a comprehen-
sive definition of multimorbidity in family medicine and long
term care, following a systematic review of relevant litera-
ture. J Am Med Dir Assoc 2013; 14(5): 319–325. DOI: 10.
1016/j.jamda.2013.01.001.
30. Piette JD and Kerr EA. The impact of comorbid chronic
conditions on diabetes care. Diabetes care 2006; 29(3):
725–731. http://www.ncbi.nlm.nih.gov/pubmed/16505540
(accessed 8 January 2018).
31. Diederichs CP, Wellmann J, Bartels DB, et al. How to weight
chronic diseases in multimorbidity indices? Development of
a new method on the basis of individual data from five
population-based studies. J Clin Epidemiol 2012; 65(6):
679–685. DOI: 10.1016/j.jclinepi.2011.11.006.
32. Luijks H, Schermer T, Bor H, et al. Prevalence and incidence
density rates of chronic comorbidity in type 2 diabetes
patients: an exploratory cohort study. BMC Med 2012; 10:
128. DOI: 10.1186/1741-7015-10-128.
33. Klein R, Klein BE, Moss SE, et al. The beaver dam eye study.
Retinopathy in adults with newly discovered and previously
diagnosed diabetes mellitus. Ophthalmology 1992; 99(1):
58–62. http://www.ncbi.nlm.nih.gov/pubmed/1741141
(accessed 8 January 2018).
34. Fortin M, Bravo G, Hudon C, et al. Relationship between
multimorbidity and health-related quality of life of patients
in primary care. Qual Life Res 2006; 15(1): 83–91. DOI: 10.
1007/s11136-005-8661-z.
35. Fortin M, Bravo G, Hudon C, et al. Prevalence of multimor-
bidity among adults seen in family practice. Ann Fam Med
2005; 3(3): 223–228. DOI: 10.1370/afm.272.
36. Lawson KD, Mercer SW, Wyke S, et al. Double trouble: the
impact of multimorbidity and deprivation on preference-
weighted health related quality of life a cross sectional anal-
ysis of the Scottish Health Survey. Int J Equity Health 2013;
12: 67. DOI: 10.1186/1475-9276-12-67.
37. van den Akker M, Buntinx F, Metsemakers JF, et al. Psycho-
social patient characteristics and GP-registered chronic mor-
bidity: a prospective study. J Psychosom Res 2001; 50(2):
95–102. http://www.ncbi.nlm.nih.gov/pubmed/11274666
(accessed 8 January 2018).
38. Larsen JR, Siersma VD, Davidsen AS, et al. The excess mor-
tality of patients with diabetes and concurrent psychiatric
illness is markedly reduced by structured personal diabetes
care: a 19-year follow up of the randomized controlled study
Diabetes Care in General Practice (DCGP). Gen Hosp Psy-
chiat 2016; 38: 42–52. DOI: 10.1016/j.genhosppsych.2015.
10.001.
39. Liddy C, Blazkho V and Mill K. Challenges of self-
management when living with multiple chronic conditions:
systematic review of the qualitative literature. Can Fam Phy-
sician 2014; 60(12): 1123–1133. http://www.ncbi.nlm.nih.
gov/pubmed/25642490 (accessed 8 January 2018).
40. Smith SM, Wallace E, O’Dowd T, et al. Interventions for
improving outcomes in patients with multimorbidity in pri-
mary care and community settings. Cochrane Db Syst Rev
2016; 3: Cd006560. DOI: 10.1002/14651858.CD006560.
pub3.
41. Muth C, van den Akker M, Blom JW, et al. The Ariadne
principles: how to handle multimorbidity in primary care
consultations. BMC Med 2014; 12: 223. DOI: 10.1186/
s12916-014-0223 -1.
42. Wallace E, Salisbury C, Guthrie B, et al. Managing patients
with multimorbidity in primary care. BMJ 2015; 350: h176.
DOI: 10.1136/bmj.h176.
43. Powell H, Lim LL and Heller RF. Accuracy of administrative
data to assess comorbidity in patients with heart disease. An
Australian perspective. J Clin Epidemiol 2001; 54(7):
687–693. http://www.ncbi.nlm.nih.gov/pubmed/11438409
(accessed 8 January 2018).
44. Prior A, Fenger-Gron M, Larsen KK, et al. The association
between perceived stress and mortality among people with
multimorbidity: a prospective population-based cohort study.
Am J Epidemiol 2016; 184(3): 199–210. DOI: 10.1093/aje/
kwv324.
Pouplier et al. 9
